nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—DDR1—uterine cervix—fallopian tube cancer	0.0306	0.0306	CbGeAlD
Imatinib—ABCA3—endometrium—fallopian tube cancer	0.03	0.03	CbGeAlD
Imatinib—DDR1—endometrium—fallopian tube cancer	0.0277	0.0277	CbGeAlD
Imatinib—DDR1—uterus—fallopian tube cancer	0.0255	0.0255	CbGeAlD
Imatinib—HIPK4—female reproductive system—fallopian tube cancer	0.0251	0.0251	CbGeAlD
Imatinib—ABCA3—female gonad—fallopian tube cancer	0.0226	0.0226	CbGeAlD
Imatinib—ABCA3—vagina—fallopian tube cancer	0.0225	0.0225	CbGeAlD
Imatinib—DDR1—female gonad—fallopian tube cancer	0.0209	0.0209	CbGeAlD
Imatinib—DDR1—vagina—fallopian tube cancer	0.0207	0.0207	CbGeAlD
Imatinib—PIP4K2C—uterine cervix—fallopian tube cancer	0.0189	0.0189	CbGeAlD
Imatinib—CA3—uterine cervix—fallopian tube cancer	0.018	0.018	CbGeAlD
Imatinib—PIP4K2C—endometrium—fallopian tube cancer	0.0171	0.0171	CbGeAlD
Imatinib—LCK—uterine cervix—fallopian tube cancer	0.0168	0.0168	CbGeAlD
Imatinib—CA3—uterus—fallopian tube cancer	0.015	0.015	CbGeAlD
Imatinib—PIP4K2C—female reproductive system—fallopian tube cancer	0.0142	0.0142	CbGeAlD
Imatinib—LCK—uterus—fallopian tube cancer	0.014	0.014	CbGeAlD
Imatinib—NQO2—uterine cervix—fallopian tube cancer	0.0139	0.0139	CbGeAlD
Imatinib—ABL2—female gonad—fallopian tube cancer	0.0136	0.0136	CbGeAlD
Imatinib—ABL2—vagina—fallopian tube cancer	0.0135	0.0135	CbGeAlD
Imatinib—CA9—female reproductive system—fallopian tube cancer	0.0129	0.0129	CbGeAlD
Imatinib—PIP4K2C—female gonad—fallopian tube cancer	0.0129	0.0129	CbGeAlD
Imatinib—PIP4K2C—vagina—fallopian tube cancer	0.0128	0.0128	CbGeAlD
Imatinib—NQO2—endometrium—fallopian tube cancer	0.0125	0.0125	CbGeAlD
Imatinib—CA3—vagina—fallopian tube cancer	0.0122	0.0122	CbGeAlD
Imatinib—CSF1R—uterine cervix—fallopian tube cancer	0.0122	0.0122	CbGeAlD
Imatinib—NQO2—uterus—fallopian tube cancer	0.0116	0.0116	CbGeAlD
Imatinib—PDGFRA—uterus—fallopian tube cancer	0.0115	0.0115	CbGeAlD
Imatinib—LCK—female gonad—fallopian tube cancer	0.0114	0.0114	CbGeAlD
Imatinib—LCK—vagina—fallopian tube cancer	0.0114	0.0114	CbGeAlD
Imatinib—KIT—epithelium—fallopian tube cancer	0.0112	0.0112	CbGeAlD
Imatinib—SLC47A1—uterine cervix—fallopian tube cancer	0.0111	0.0111	CbGeAlD
Imatinib—KIT—uterine cervix—fallopian tube cancer	0.0111	0.0111	CbGeAlD
Imatinib—CSF1R—endometrium—fallopian tube cancer	0.011	0.011	CbGeAlD
Imatinib—PDGFRB—epithelium—fallopian tube cancer	0.0109	0.0109	CbGeAlD
Imatinib—PDGFRB—uterine cervix—fallopian tube cancer	0.0108	0.0108	CbGeAlD
Imatinib—NQO2—female reproductive system—fallopian tube cancer	0.0104	0.0104	CbGeAlD
Imatinib—PDGFRA—female reproductive system—fallopian tube cancer	0.0104	0.0104	CbGeAlD
Imatinib—CSF1R—uterus—fallopian tube cancer	0.0102	0.0102	CbGeAlD
Imatinib—SLC47A1—endometrium—fallopian tube cancer	0.0101	0.0101	CbGeAlD
Imatinib—KIT—endometrium—fallopian tube cancer	0.01	0.01	CbGeAlD
Imatinib—PDGFRB—endometrium—fallopian tube cancer	0.00977	0.00977	CbGeAlD
Imatinib—ABL1—uterine cervix—fallopian tube cancer	0.00963	0.00963	CbGeAlD
Imatinib—CA12—female reproductive system—fallopian tube cancer	0.00957	0.00957	CbGeAlD
Imatinib—NQO2—female gonad—fallopian tube cancer	0.00946	0.00946	CbGeAlD
Imatinib—PDGFRA—female gonad—fallopian tube cancer	0.00943	0.00943	CbGeAlD
Imatinib—NQO2—vagina—fallopian tube cancer	0.0094	0.0094	CbGeAlD
Imatinib—PDGFRA—vagina—fallopian tube cancer	0.00938	0.00938	CbGeAlD
Imatinib—SLC47A1—uterus—fallopian tube cancer	0.00927	0.00927	CbGeAlD
Imatinib—KIT—uterus—fallopian tube cancer	0.00922	0.00922	CbGeAlD
Imatinib—ORM1—endometrium—fallopian tube cancer	0.00917	0.00917	CbGeAlD
Imatinib—CSF1R—female reproductive system—fallopian tube cancer	0.00913	0.00913	CbGeAlD
Imatinib—PDGFRB—uterus—fallopian tube cancer	0.009	0.009	CbGeAlD
Imatinib—ABL1—endometrium—fallopian tube cancer	0.00871	0.00871	CbGeAlD
Imatinib—SLC47A1—female reproductive system—fallopian tube cancer	0.00834	0.00834	CbGeAlD
Imatinib—CSF1R—female gonad—fallopian tube cancer	0.00831	0.00831	CbGeAlD
Imatinib—KIT—female reproductive system—fallopian tube cancer	0.00829	0.00829	CbGeAlD
Imatinib—CSF1R—vagina—fallopian tube cancer	0.00825	0.00825	CbGeAlD
Imatinib—PDGFRB—female reproductive system—fallopian tube cancer	0.00809	0.00809	CbGeAlD
Imatinib—ABL1—uterus—fallopian tube cancer	0.00803	0.00803	CbGeAlD
Imatinib—ORM1—female reproductive system—fallopian tube cancer	0.00759	0.00759	CbGeAlD
Imatinib—SLC47A1—female gonad—fallopian tube cancer	0.00758	0.00758	CbGeAlD
Imatinib—CA1—female reproductive system—fallopian tube cancer	0.00758	0.00758	CbGeAlD
Imatinib—KIT—female gonad—fallopian tube cancer	0.00754	0.00754	CbGeAlD
Imatinib—SLC47A1—vagina—fallopian tube cancer	0.00754	0.00754	CbGeAlD
Imatinib—KIT—vagina—fallopian tube cancer	0.0075	0.0075	CbGeAlD
Imatinib—PDGFRB—female gonad—fallopian tube cancer	0.00737	0.00737	CbGeAlD
Imatinib—PDGFRB—vagina—fallopian tube cancer	0.00732	0.00732	CbGeAlD
Imatinib—ABL1—female reproductive system—fallopian tube cancer	0.00721	0.00721	CbGeAlD
Imatinib—CA2—epithelium—fallopian tube cancer	0.00661	0.00661	CbGeAlD
Imatinib—ABL1—female gonad—fallopian tube cancer	0.00657	0.00657	CbGeAlD
Imatinib—ABL1—vagina—fallopian tube cancer	0.00653	0.00653	CbGeAlD
Imatinib—SLC22A1—vagina—fallopian tube cancer	0.00629	0.00629	CbGeAlD
Imatinib—ABCG2—uterine cervix—fallopian tube cancer	0.00607	0.00607	CbGeAlD
Imatinib—CYP3A5—uterine cervix—fallopian tube cancer	0.00564	0.00564	CbGeAlD
Imatinib—ABCG2—endometrium—fallopian tube cancer	0.00549	0.00549	CbGeAlD
Imatinib—PTGS1—epithelium—fallopian tube cancer	0.00511	0.00511	CbGeAlD
Imatinib—PTGS1—uterine cervix—fallopian tube cancer	0.00506	0.00506	CbGeAlD
Imatinib—ABCG2—uterus—fallopian tube cancer	0.00506	0.00506	CbGeAlD
Imatinib—CA2—female reproductive system—fallopian tube cancer	0.00491	0.00491	CbGeAlD
Imatinib—CYP2C19—vagina—fallopian tube cancer	0.00485	0.00485	CbGeAlD
Imatinib—PTGS1—endometrium—fallopian tube cancer	0.00458	0.00458	CbGeAlD
Imatinib—CA2—female gonad—fallopian tube cancer	0.00447	0.00447	CbGeAlD
Imatinib—CA2—vagina—fallopian tube cancer	0.00444	0.00444	CbGeAlD
Imatinib—PTGS1—uterus—fallopian tube cancer	0.00422	0.00422	CbGeAlD
Imatinib—CYP2C9—female reproductive system—fallopian tube cancer	0.00416	0.00416	CbGeAlD
Imatinib—ABCG2—female gonad—fallopian tube cancer	0.00414	0.00414	CbGeAlD
Imatinib—ABCG2—vagina—fallopian tube cancer	0.00411	0.00411	CbGeAlD
Imatinib—CYP3A5—female gonad—fallopian tube cancer	0.00384	0.00384	CbGeAlD
Imatinib—CYP3A5—vagina—fallopian tube cancer	0.00382	0.00382	CbGeAlD
Imatinib—PTGS1—female reproductive system—fallopian tube cancer	0.00379	0.00379	CbGeAlD
Imatinib—PTGS1—female gonad—fallopian tube cancer	0.00345	0.00345	CbGeAlD
Imatinib—PTGS1—vagina—fallopian tube cancer	0.00343	0.00343	CbGeAlD
Imatinib—CYP3A4—female reproductive system—fallopian tube cancer	0.00317	0.00317	CbGeAlD
Imatinib—CYP2D6—female reproductive system—fallopian tube cancer	0.00312	0.00312	CbGeAlD
Imatinib—ABCB1—epithelium—fallopian tube cancer	0.00302	0.00302	CbGeAlD
Imatinib—ABCB1—uterine cervix—fallopian tube cancer	0.00299	0.00299	CbGeAlD
Imatinib—CYP2D6—female gonad—fallopian tube cancer	0.00284	0.00284	CbGeAlD
Imatinib—ABCB1—endometrium—fallopian tube cancer	0.00271	0.00271	CbGeAlD
Imatinib—ABCB1—uterus—fallopian tube cancer	0.0025	0.0025	CbGeAlD
Imatinib—ABCB1—female reproductive system—fallopian tube cancer	0.00224	0.00224	CbGeAlD
Imatinib—ABCB1—female gonad—fallopian tube cancer	0.00204	0.00204	CbGeAlD
Imatinib—ABCB1—vagina—fallopian tube cancer	0.00203	0.00203	CbGeAlD
